Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 18/20 | 0.81 |
| ▸ | RXRG | P48443 | 13/20 | 0.81 |
| ▸ | RXRB | P28702 | 12/20 | 0.81 |
| ▸ | HNF4A | P41235 | 3/20 | 0.60 |
| ▸ | ESR1 | P03372 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5533610 | 0.94 | RXRA (0.81) | RXRARXRGRXRBHNF4AESR1 | |
| SCHEMBL6891713 | 0.90 | RXRA (1.00) | RXRARXRGRXRBHNF4AESR1 | |
| SCHEMBL726357 | 0.90 | RXRA (1.00) | RXRARXRGRXRBHNF4AESR1 | |
| SCHEMBL6917916 | 0.87 | RXRA (0.94) | RXRARXRGRXRBHNF4AESR1 | |
| SCHEMBL6916392 | 0.85 | RXRA (0.76) | RXRARXRGRXRBHNF4A | |
| SCHEMBL6889557 | 0.84 | RXRA (1.00) | RXRARXRGRXRBHNF4AESR1 | |
| SCHEMBL5534972 | 0.82 | RXRA (0.82) | RXRARXRGRXRBHNF4AESR1 | |
| SCHEMBL5540507 | 0.82 | RXRA (0.79) | RXRARXRGRXRBHNF4AESR1 | |
| SCHEMBL5540407 | 0.81 | RXRA (0.88) | RXRARXRGRXRBHNF4AESR1 | |
| SCHEMBL6890200 | 0.78 | RXRA (1.00) | RXRARXRGRXRBHNF4AESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140235676-A1 | RXR AGONIST COMPOUNDS AND METHODS | UNIV CASE WESTERN RESERVE (US) | 2014-08-21 | — | — | US | disclosed |
| US-20120115912-A1 | RXR AGONIST COMPOUNDS AND METHODS | LANDRETH GARY E (US) | 2012-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140235676-A1 | RXR AGONIST COMPOUNDS AND METHODS | RXRA, RXRB, RXRG | RXRA 1/4885RXRG 3/4885RXRB 2/4885 |
| US-20120115912-A1 | RXR AGONIST COMPOUNDS AND METHODS | RXRA, RXRB, RXRG | RXRA 1/4885RXRG 3/4885RXRB 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.